Patient usefulness first.
Commercial influence never.
MedicineCostHelp exists to help people understand the access path around expensive medicines. Editorial decisions are based on usefulness, evidence and patient-access relevance—not on who advertises.
We explain the system without pretending to be the system.
MedicineCostHelp may summarize coverage criteria, benefit routing, coding considerations, manufacturer assistance and independent funding so users can identify the next place to verify an answer. We do not make an insurer’s coverage determination, prescribe treatment, guarantee reimbursement, guarantee foundation availability or tell a patient to substitute one therapy for another.
Medication pages should add practical value: the exact medicine/formulation, likely benefit path, common access barriers, official sources, assistance options and clear next steps. We avoid thin pages created only to capture search traffic.
When evidence is incomplete or plan-specific, the page should say so plainly and direct the user to the controlling organization.
Detection can be automated. Meaning requires review.
Added when a medicine or access question is important enough to help real patients—not to inflate page count.
Automated monitors may flag changes, but patient-facing guidance changes only after review.
Priority goes to changes that affect coverage, preferred products, coding, site of care, assistance or next actions.
We distinguish confirmed facts from plan-specific items that must be verified.
Substantive errors are corrected when confirmed; the monitoring baseline is advanced only after review.
Editorial standards apply whether or not a company, payer, foundation or other organization has a commercial relationship with MedicineCostHelp.
The standard is useful, current and defensible.
Important factual claims should be traceable to authoritative public sources. Content should use meaningful review dates when a real review occurred. Corrections and broken-source reports are accepted through the public contact pathway.
As MedicineCostHelp approaches broad public launch, reviewer/author expertise and formal editorial governance should be made even more explicit where appropriate. No credential or reviewer identity should be invented or implied before that information is formally established.